Dare Bioscience, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Dare Bioscience, Inc. (DARE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $32.24 per share for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2019-11-12
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2019-03-31 was $17.81.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2017-03-31 was $4.21, a 13.73% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2016-03-31 was $4.88, a 14.83% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2015-03-31 was $5.73, a 0.52% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2017 was $54.25, a 1216.75% increase from fiscal 2016.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2016 was $4.12, a 29.69% decline from fiscal 2015.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2015 was $5.86, a 20.82% increase from fiscal 2014.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2014 was $4.85.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2019-09-30 | $32.24 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $24.55 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $17.81 10-Q · filed 2019-05-14 | |||
| 2018-09-30 | $59.48 10-Q · filed 2018-11-13 | |||
| 2017-12-31 | $54.25 10-K · filed 2018-03-28 | |||
| 2017-09-30 | $51.38 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | $42.09 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | $4.21 10-Q · filed 2017-05-12 | |||
| 2016-12-31 | $4.12 10-K/A · filed 2017-06-13 | |||
| 2016-09-30 | $4.27 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $4.46 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $4.88 10-Q · filed 2016-05-02 | |||
| 2015-12-31 | $5.86 10-K · filed 2016-03-10 | |||
| 2015-09-30 | $5.83 10-Q · filed 2015-11-16 | |||
| 2015-06-30 | $5.36 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $5.73 10-Q · filed 2015-05-06 | |||
| 2014-12-31 | $4.85 10-K · filed 2015-03-19 | |||
| 2014-09-30 | $4.85 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $7.35 10-Q · filed 2014-08-12 | |||
| 2014-03-31 | $5.76 10-Q · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |